Discovery of a potent, selective, and orally available EGFR C797S mutant inhibitor (DS06652923) with in vivo antitumor activity-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Discovery of a potent, selective, and orally available EGFR C797S mutant inhibitor (DS06652923) with in vivo antitumor activity

Published:2024-09 Issue: Volume:111 Page:117862
ISSN:0968-0896
Container-title:Bioorganic & Medicinal Chemistry
language:en
Short-container-title:Bioorganic & Medicinal Chemistry

Author:

Kageji Hideaki,Momose Takayuki,Ebisawa Masayuki,Nakazawa Yusuke,Okada Hiroyuki,Togashi Noriko,Nagamoto Yasuhito,Obuchi Wataru,Yasumatsu Isao,Kihara Kawori,Hiramoto Kumiko,Minami Megumi,Kasanuki Naomi,Isoyama Takeshi,Naito Hiroyuki,Tanaka Naoki

Publisher

Elsevier BV

Reference50 articles.

1. Epidemiological trends of tracheal, bronchus, and lung cancer at the global, regional, and national levels: a population-based study;Deng;Journal of Hematology & Oncology,2020

2. The prevalence of EGFR mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis;Zhang;Oncotarget,2016

3. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII);Midha;American Journal of Cancer Research,2015

4. Overview of current systemic management of EGFR-mutant NSCLC;Hsu;Annals of Oncology,2018

5. EGFR fusions as novel therapeutic targets in lung cancer;Konduri;Cancer Discovery,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP